{"id":53608,"date":"2023-02-03T12:02:35","date_gmt":"2023-02-03T11:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/north-america-gastrointestinal-therapeutics-market-research-report-2022-researchandmarkets-com\/"},"modified":"2023-02-03T12:02:35","modified_gmt":"2023-02-03T11:02:35","slug":"north-america-gastrointestinal-therapeutics-market-research-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/north-america-gastrointestinal-therapeutics-market-research-report-2022-researchandmarkets-com\/","title":{"rendered":"North America Gastrointestinal Therapeutics Market Research Report 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “North America Gastrointestinal Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Distribution Channel, By Route of Administration (Injectable and Oral & Others), By Application, By Drug Class, By Country and Growth Forecast, 2022 – 2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe North America Gastrointestinal Therapeutics Market should witness market growth of 2.6% CAGR during the forecast period (2022-2028).\n<\/p>\n

\nThe US market dominated the North America Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $11, 546.6 million by 2028. The Canada market is poised to grow at a CAGR of 4.9% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 4% during (2022-2028).\n<\/p>\n

\nIn many ways, the intestinal milieu represents a microcosm of the whole body. It possesses its intrinsic endocrine and nervous system, its barrier both to internal and external environments of the body, and its own intrinsic mucosal immune system, namely the so-called gut-associated lymphoid tissue (GALT).\n<\/p>\n

\nEach of these enteric systems can account for pathophysiology and contribute to digestive disorders’ clinical picture. Thus, therapeutic intervention for the disease of the GI tract is particularly demanding and should be strategically targeted, with the potential for drug side effects representing considerable accountability.\n<\/p>\n

\nGastrointestinal (GI) disease may affect one or more gastrointestinal tract regions, including the esophagus, small & large intestine, stomach, or accessory organs such as the pancreas, gallbladder, and liver. This disease class includes both structural and functional disorders. In addition, GI disorders may arise from diverse etiologies, including pathogens exposure, certain medications, stress, diet, abnormal cell growth, and more.\n<\/p>\n

\nTo foster safe usage of the over-the-counter (OTC) anti-diarrhea drug loperamide, the U.S. Food and Drug Administration (FDA) is collaborating with manufacturers to use blister packs or other single-dose packaging and to limit the number of doses in a package. Loperamide is an FDA-approved medication used to control diarrhea symptoms, including Travelers’ diarrhea.\n<\/p>\n

\nKey Market Players<\/strong>\n<\/p>\n